New hope for tough myeloma: Two-Drug combo takes on relapsed disease
NCT ID NCT06948084
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 34 times
Summary
This study compares a new two-drug combination (daratumumab and teclistamab) against standard three-drug treatments for people with high-risk multiple myeloma that has returned or not responded to initial therapy. About 80 adults who have had only one prior treatment line will be randomly assigned to receive either the new combo or one of the usual regimens. The goal is to see if the new approach can reduce cancer cells to undetectable levels more effectively.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.